 | • レポートコード：MRC2303J0172 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に4,347.46百万ドルであった世界のアレルギー性鼻炎治療薬市場規模は、2022年に4,543.02百万ドルになり、2027年までにCAGR 4.67％で拡大して5,718.77百万ドルに達するとみられています。本書は、アレルギー性鼻炎治療薬の世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、投与経路別（経鼻、眼内、経口、非経口）分析、薬剤分類別（抗ヒスタミン薬、免疫療法、鼻腔内コルチコステロイド）分析、用途別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、A-S Medication Solutions、Adamis Pharmaceuticals、Alcon、Amneal Pharmaceuticals LLC、Apotex Corp、Ascend Laboratories, LLC、AvKARE、Belcher Pharmaceuticals、Bristol Myers Squibb Pharma、Dr. Reddy’s Laboratories, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のアレルギー性鼻炎治療薬市場規模：投与経路別 - 経鼻投与の市場規模 - 眼内投与の市場規模 - 経口投与の市場規模 - 非経口投与の市場規模 ・世界のアレルギー性鼻炎治療薬市場規模：薬剤分類別 - 抗ヒスタミン薬の市場規模 - 免疫療法の市場規模 - 鼻腔内コルチコステロイドの市場規模 ・世界のアレルギー性鼻炎治療薬市場規模：用途別 - 病院薬局における市場規模 - オンライン薬局における市場規模 - 小売薬局における市場規模 ・世界のアレルギー性鼻炎治療薬市場規模：地域別 - 南北アメリカのアレルギー性鼻炎治療薬市場規模 アメリカのアレルギー性鼻炎治療薬市場規模 カナダのアレルギー性鼻炎治療薬市場規模 ブラジルのアレルギー性鼻炎治療薬市場規模 ... - アジア太平洋のアレルギー性鼻炎治療薬市場規模 日本のアレルギー性鼻炎治療薬市場規模 中国のアレルギー性鼻炎治療薬市場規模 インドのアレルギー性鼻炎治療薬市場規模 韓国のアレルギー性鼻炎治療薬市場規模 台湾のアレルギー性鼻炎治療薬市場規模 ... - ヨーロッパ/中東/アフリカのアレルギー性鼻炎治療薬市場規模 イギリスのアレルギー性鼻炎治療薬市場規模 ドイツのアレルギー性鼻炎治療薬市場規模 フランスのアレルギー性鼻炎治療薬市場規模 ロシアのアレルギー性鼻炎治療薬市場規模 ... - その他地域のアレルギー性鼻炎治療薬市場規模 ・競争状況 ・企業情報 |
The Global Allergic Rhinitis Drugs Market size was estimated at USD 4,347.46 million in 2021 and expected to reach USD 4,543.02 million in 2022, and is projected to grow at a CAGR 4.67% to reach USD 5,718.77 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Allergic Rhinitis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Route of Administration, the market was studied across Intranasal, Intraocular, Oral, and Parenteral.
Based on Class of Drugs, the market was studied across Antihistamines, Immunotherapies, and Intranasal Corticosteroids.
Based on Application, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Allergic Rhinitis Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Allergic Rhinitis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Allergic Rhinitis Drugs Market, including A-S Medication Solutions, Adamis Pharmaceuticals, Alcon, Amneal Pharmaceuticals LLC, Apotex Corp, Ascend Laboratories, LLC, AvKARE, Belcher Pharmaceuticals, Bristol Myers Squibb Pharma, Dr. Reddy’s Laboratories, Inc., Fosun Pharma USA Inc, Gland Pharma Limited, GlaxoSmithKline, Janssen Biotech, Inc., MEDA Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Mylan Pharmaceuticals Inc., Novartis, Perrigo New York Inc., Pfizer, Physicians Total Care, Inc., Sandoz Inc, Sanofi, Shoreline Pharmaceuticals, Inc., and Sun Pharmaceutical Industries, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Allergic Rhinitis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Allergic Rhinitis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Allergic Rhinitis Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Allergic Rhinitis Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Allergic Rhinitis Drugs Market?
6. What is the market share of the leading vendors in the Global Allergic Rhinitis Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Allergic Rhinitis Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of allergic rhinitis
5.1.1.2. Increasing lifestyle changes attributes to growing use of tobacco promotes allergic rhinitis
5.1.1.3. Availability of different modes of administration such as nasal sprays increases demand for allergic rhinitis drugs
5.1.1.4. Demand for over-the-counter drugs
5.1.2. Restraints
5.1.2.1. Reduced specificity of symptoms for allergic rhinitis
5.1.3. Opportunities
5.1.3.1. Growing development and commercialization of allergic rhinitis drugs
5.1.3.2. Increasing government and organization initiatives to increase the awareness of allergic rhinitis
5.1.4. Challenges
5.1.4.1. No standard cure for allergic rhinitis
5.2. Cumulative Impact of COVID-19
6. Allergic Rhinitis Drugs Market, by Route of Administration
6.1. Introduction
6.2. Intranasal
6.3. Intraocular
6.4. Oral
6.5. Parenteral
7. Allergic Rhinitis Drugs Market, by Class of Drugs
7.1. Introduction
7.2. Antihistamines
7.3. Immunotherapies
7.4. Intranasal Corticosteroids
8. Allergic Rhinitis Drugs Market, by Application
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Americas Allergic Rhinitis Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Allergic Rhinitis Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Allergic Rhinitis Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. A-S Medication Solutions
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Adamis Pharmaceuticals
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Alcon
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Amneal Pharmaceuticals LLC
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Apotex Corp
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Ascend Laboratories, LLC
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. AvKARE
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Belcher Pharmaceuticals
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Bristol Myers Squibb Pharma
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Dr. Reddy’s Laboratories, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Fosun Pharma USA Inc
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Gland Pharma Limited
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Janssen Biotech, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. MEDA Pharmaceuticals
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mitsubishi Tanabe Pharma
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Mylan Pharmaceuticals Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Novartis
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Perrigo New York Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Pfizer
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Physicians Total Care, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Sandoz Inc
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Sanofi
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Shoreline Pharmaceuticals, Inc.
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Sun Pharmaceutical Industries, Inc.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing